23.12.2016
Eckert & Ziegler Strahlen- und Medizintechnik AG DE0005659700
DGAP-News: Eckert & Ziegler: New Executive Board member for Radiation Therapy. Harald Hasselmann succeeds Edgar Löffler.
DGAP-News: Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s):
Change of Personnel
Eckert & Ziegler: New Executive Board member for Radiation Therapy. Harald
Hasselmann succeeds Edgar Löffler.
23.12.2016 / 17:40
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Berlin, December 23, 2016 - The Supervisory Board of Eckert & Ziegler AG
has appointed Dr. Harald Hasselman (49) as the new Executive Board member
for the Radiation Therapy segment with effect from January 1, 2017. He
succeeds Dr. Edgar Löffler (63), who will retire from the company as
planned at the end of 2016, thereby stepping down from his duties.
Dr. Löffler will continue to be available to the company under a consulting
agreement.
"Since 2001, Dr. Löffler has played an instrumental role in the development
of our Therapy segment and in establishing Eckert & Ziegler as a major,
globally active provider of cancer radiation systems," company founder and
Chairman of the Executive Board Dr. Andreas Eckert said. "Our success as
the European market leader in prostate implants would have been
inconceivable without him. The Executive and Supervisory Boards would like
to thank Edgar Löffler for these achievements and look forward to
continuing to have him at their side."
Dr. Hasselmann has worked for the Eckert & Ziegler Group since 2015. As the
Commercial Managing Director of Eckert & Ziegler BEBIG GmbH, he has
successfully implemented the realignment of the specialist for
brachytherapy. Hasselmann, a native of Hamburg, has many years of
experience at international pharmaceutical companies. His positions include
head of controlling for Europe at Bayer Pharma, managing director at
Schering's Hungarian subsidiary, and director of the Berlin-based biotech
company metaGen. He has held various positions at large and medium-sized
healthcare companies and has a proven track record in sales, controlling,
and implementing restructuring measures.
About Eckert & Ziegler.
Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700), with
approximately 670 employees, is one the world's largest providers of
isotope technology for radiation therapy and nuclear medicine.
Contributing to saving lives.
Your contact:
Eckert & Ziegler AG, Karolin Riehle, Investor Relations
Robert-Rössle-Str. 10, 13125 Berlin, Germany
Tel.: +49 (0) 30 / 94 10 84-138, [email protected], www.ezag.de
---------------------------------------------------------------------------
23.12.2016 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Eckert & Ziegler Strahlenund Medizintechnik AG
Robert-Rössle-Str.10
13125 Berlin
Germany
Phone: 49 30 941084-138
Fax: 49 30 941084-112
E-mail: [email protected]
Internet: www.ezag.de
ISIN: DE0005659700
WKN: 565970
Listed: Regulated Market in Frankfurt (Prime Standard), Stuttgart;
Regulated Unofficial Market in Berlin, Dusseldorf,
Hamburg, Munich, Tradegate Exchange
End of News DGAP News Service
---------------------------------------------------------------------------
532923 23.12.2016
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
Eckert & Ziegler Strahlen- und Medizintechnik AG ISIN: DE0005659700 können Sie bei EQS abrufen
Medtech , 565970 , EUZ , XETR:EUZ